Clinical trials: Marijuana
Multiple Sclerosis, Neuropathic Pain
A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis
To investigate the ability of Sativex to relieve central neuropathic pain in multiple sclerosis subjects.
- Trial name
- NCT01604265
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 66 people
- Sponsor
- Jazz Pharmaceuticals
Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4
Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex
Study to assess the effect of rifampicin, ketoconazole and omeprazole on the pharmacokinetics of a single dose of Sativex and to evaluate the safety of Sativex when given in combination with these other drugs.
- Conditions
- Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor
- Trial name
- NCT01323465
- Testing
- Sativex and rifampicin, Sativex and ketoconazole, Sativex and omeprazole
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Jazz Pharmaceuticals
Autistic Disorder
A Trial to Assess the Efficacy and Safety of Medical Grade Cannabis in Children Diagnosed With Autism Spectrum Disorder
This single center, double-blinded, randomized, placebo-controlled crossover trial will assess the efficacy and safety of extraction of cannabis flowers dissolved in olive oil (30% CBD and 1.5% Δ9-THC) vs.
- Trial name
- NCT05413187
- Testing
- Medical Grade Cannabis oil
- Where
- Israel
- Volunteers
- healthy volunteers welcome
- Sponsor
- TO Pharmaceuticals
Healthy Volunteers
Safety and Pharmacokinetics of Smoked Cannabis in Healthy Patients
No actual human data for pharmacokinetics, metabolism, safety, pharmacodynamics, nor efficacy parameters are available for inhaled medical cannabis.
- Trial name
- NCT04314804
- Testing
- PPP001
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Tetra Bio-Pharma
Autism, Autism Spectrum Disorder
NTI164 in Autism Spectrum Disorder
This is a double-blind, randomised, placebo-controlled study investigating the efficacy of a full-spectrum medicinal cannabis plant extract on core and associated ASD symptoms over placebo.
- Conditions
- Autism, Autism Spectrum Disorder, Autism Disorder
- Trial name
- Beyond Harmony (NCT07257939)
- Testing
- NTI164
- Where
- 3 sites in Australia
- Volunteers
- 200 people
- Sponsor
- Fenix Innovation Group
Palliative Care, Pain
A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.
The purpose of this study is to determine the effective dose range and to demonstrate a non-effective dose range of Sativex in patients with advanced cancer, who experience inadequate pain relief even though they are on optimized…
- Conditions
- Palliative Care, Pain, Cancer
- Trial name
- SPRAY (NCT00530764)
- Testing
- Sativex Low Dose, Sativex Medium Dose, Sativex High Dose
- Where
- 110 sites in United States, Belgium and 14 more
- Volunteers
- 360 people
- Sponsor
- GW Pharmaceuticals Ltd
Tuberous Sclerosis Complex (TSC)
Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)
1. To assess treatment efficacy with YCJ-01 by changes in the number of epileptic seizures in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex. 2.
- Trial name
- Spectrum (NCT07403266)
- Testing
- YCJ-01 Full Spectrum cannbis Extract
- Where
- Spain
- Volunteers
- 84 people
- Sponsor
- Oils4Cure
Cancer Pain, Quality of Life
Safety and Efficacy of Inhaled Cannabis For the Uncontrolled Pain Relief in Patients With Advanced Cancer
This phase 2 multicenter clinical trial assess the safety and efficacy of inhaled PPP001 to relieve the pain in 78 advanced cancer patients with uncontrolled symptoms.
- Conditions
- Cancer Pain, Quality of Life, Pain, Acute, Cannabis Use
- Trial name
- PLENITUDE (NCT04042545)
- Testing
- PPP001
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Tetra Bio-Pharma
Addiction, Opioid Dependence
Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction
The purpose of this study is determine the safety, efficacy and tolerability of a novel drug APH-1501 as a pharmacotherapy for Opioid Dependence. The investigators will evaluate the safety of escalating doses APH-1501.
- Conditions
- Addiction, Opioid Dependence, Opioid Withdrawal
- Trial name
- NCT03813095
- Testing
- APH-1501
- Volunteers
- 32 people
- Sponsor
- Aphios
Generalized Anxiety Disorder
Anxiety Symptoms in Relation to Use of Hemp-derived, Full Spectrum Cannabidiol (CBD)
Generalized anxiety disorder affects about 6.8 million adults in the United States, therefore its treatment is of major public health interest.
- Trial name
- NCT05023759
- Testing
- Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 30 people
- Sponsor
- Formula30A LLC
Smoking Cessation, Marijuana Use
Project CheckUP: A Brief Behavioral Intervention for Quitline Callers Who Use Marijuana (MJ) and Tobacco
Smoking cigarettes remains the number one preventable cause of death and disease in the US. Smokers who call tobacco quitlines and use marijuana struggle to quit tobacco due to the interactive effects of nicotine and marijuana.
- Trial name
- NCT04737772
- Testing
- Behavioral: Quitline treatment as usual, QL Marijuana Check-Up intervention (QL-MJCU)
- Where
- United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Consumer Wellness Solutions
Cannabis Intoxication
Cannabis Impairment Detection Device Study
The goal of this study is to develop a cannabis impairment detection device in adult cannabis users. The main question[s] it aims to answer are: Is the investigational device accurate and reliable at detecting cannabis…
- Trial name
- NCT07122349
- Testing
- Cannabis Impairment Test
- Where
- Canada
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Gaize
Palliative Care, Pain
A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy
The purpose of this study is to determine whether Sativex® and GW-2000-02 are effective in the management of subjects with intractable cancer-related pain.
- Conditions
- Palliative Care, Pain, Cancer
- Trial name
- SPRAY (NCT00674609)
- Testing
- Sativex®, THC Alone
- Where
- United Kingdom
- Volunteers
- 177 people
- Sponsor
- Jazz Pharmaceuticals
Pain, Peripheral Neuropathy
A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain.
The purpose of this study is to assess the safety and tolerability of long term therapy with Sativex® in relieving neuropathic pain.
- Trial name
- NCT00713323
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 380 people
- Sponsor
- Jazz Pharmaceuticals
Healthy
Food Effect Study of VER-01 in Healthy Volunteers
Evaluation of pharmacokinetics, tolerability and safety of VER-01 depending on the intake a high-fat meal in healthy volunteers
- Trial name
- NCT04930796
- Testing
- VER-01
- Where
- Austria
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Vertanical GmbH
PANS Pediatric Acute-Onset Neuropsychiatric Syndrome
Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS)
This study investigates the effectiveness of a medicinal cannabis extract (NTI164) with 0.08% THC in treating children with pediatric acute-onset neuropsychiatric syndrome (PANS) over a period of 18 to 54 weeks.
- Trial name
- CannaPANS (NCT06621888)
- Testing
- NTI164
- Where
- 2 sites in Australia
- Volunteers
- 18 people
- Sponsor
- Fenix Innovation Group
ADHD, Hyperactivity
Treatment With Cannabis Oil Containing CBD, THC, CBDV or CBG vs. Placebo of Persons With ADHD
ADHD is the most frequent neuro-developmental disorder in childhood and often continues into adolescence and adulthood. Indicated drug treatments for ADHD fall into 2 categories: stimulants (such as methylphenidate and…
- Conditions
- ADHD, Hyperactivity, Attention Deficit
- Trial name
- NCT05219370
- Testing
- Cannabis oil
- Where
- Israel
- Volunteers
- 8 people
- Sponsor
- Brlev Agricultural Crops Ltd
Alcoholic Intoxication, Automobile Accident
Responsible Marijuana Sales Practices to Reduce the Risk of Selling to Intoxicated Customers
The new recreational marijuana markets are contributing to polysubstance-impaired driving and other harms, especially when marijuana is used in combination with alcohol, by selling marijuana to obviously-intoxicated customers.
- Conditions
- Alcoholic Intoxication, Automobile Accident, Cannabis
- Trial name
- NCT06235632
- Testing
- Policy and Training Intervention, Usual and Customary Policy and Training (UC-PT) (Control) Condition
- Where
- United States
- Volunteers
- 229 people
- Sponsor
- Klein Buendel, Inc.
Fibromyalgia, Cannabis
Phase II Clinical Trial, Use of KL16-012 in Women With Fibromyalgia Refractary to Conventional Treatment.
A double blind randomized placebo controlled trial in 44 women with fibromyalgia and persistent symptoms in spite of use of conventional pharmacotherapy, will be performed in the city of Valparaiso.
- Trial name
- NCT04239469
- Testing
- KL16-012
- Volunteers
- 44 people
- Sponsor
- Knop Laboratorios
Allergic Rhinitis Due to Weed Pollen, Allergic Rhinitis
Trial of INI-2004 in Healthy Volunteers and Participants With Allergic Rhinitis.
This is a Phase I/Ib, randomised, double-blind, placebo-controlled study of INI-2004, administered as single or multiple doses. This study will be conducted in two parts: Phase I single ascending dose (SAD) and Phase Ib multiple…
- Trial name
- NCT06038279
- Testing
- INI-2004
- Where
- Australia
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Inimmune Corporation